Novel antipsychotics and severe hyperlipidemia

Journal of Clinical Psychopharmacology

Volumn 21, Issue 4, 2001, Pages 369-374

  Meyer, Jonathan M ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPERLAPINE; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HUMAN; HYPERLIPIDEMIA; INCIDENCE; LIPID BLOOD LEVEL; MALE; OBESITY; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; LIPIDS; MALE; PIRENZEPINE; RETROSPECTIVE STUDIES;

EID: 0034922211     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200108000-00003     Document Type: Article

References (51)

1. Psychopharmacology: From chlorpromazine to olanzapine - A brief history of antipsychotics
2. Adverse effects of the atypical antipsychotics
3. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia
4. Clozapine and body mass change
5. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months
6. Management of the adverse effects of clozapine
7. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene
8. Serum leptin levels increase rapidly after initiation of clozapine therapy
9. Novel antipsychotics: Comparison of weight gain liabilities
10. Novel antipsychotics and new onset diabetes
11. Elevated serum triglycerides on clozapine resolve with risperidone
12. Serum triglyceride levels in patients treated with clozapine
13. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients
14. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine
15. Clozapine-associated elevation in serum triglycerides
16. Olanzapine-induced elevation of plasma triglyceride levels
17. Olanzapine increases weight and serum triglycerides
18. Nonpharmacologic treatment of hypertriglyceridemia: Focus on fish oils
19. Drug-induced hypertriglyceridemia with and without pancreatitis
20. Hyperlipidemia associated with protease inhibitor therapy
21. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics
22. Amenorrhea and elevated serum cholesterol produced by a trifluoro-methylated phenothiazine
23. Chlorpromazine in women with chronic schizophrenia: The effect on cholesterol levels and cholesterol-behavior relationships
24. The effect of three butyrophenones on serum cholesterol levels
25. Sterol metabolism: Biochemical differences among the butyrophenones
26. Trifluperidol and cholesterol in man
27. Trifluperidol in chronic male psychiatric patients
28. Further studies on the effect of butyrophenones on cholesterol synthesis in humans
29. Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines
30. Lipids and apolipoproteins in patients treated with major tranquilizers
31. A short survey on untoward effects of fluperlapine
32. Fluperlapine vs haloperidol: A comparison of their neuroendocrinological profiles and the influence on serum lipids
33. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors
34. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability
35. Body weight and leptin plasma levels during treatment with antipsychotic drugs
36. Effects of the obese gene product on body weight regulation in ob/ob mice
37. Weight-reducing effects of the plasma protein encoded by the obese gene
38. Neuropharmacology of obesity: My receptors made me eat it
39. The role of leptin in human obesity and disease: A review of current evidence
40. Association of β3-adrenoreceptor polymorphism with obesity and diabetes: Current status
41. Epidemiology of hypertriglyceridemia and cardiovascular disease
42. Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
43. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
44. Serum lipids, lipoproteins, and apolipoproteins in adult epileptics treated with carbamazepine, valproic acid, or phenytoin
45. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants
46. Serum lipids in epileptic children treated with carbamazepine and valproate
47. Does long-term lithium treatment induce diabetes mellitus?
48. The effect of short term lithium carbonate in type II diabetes mellitus
49. Antidiabetic effects of lithium
50. Lithium in diabetes mellitus: A paradoxical response